Releases

Current
2017
2016
2015
2014
22.06.2017 FN Herantis Pharma's Lymfactin study advances to last patient cohort, company announces initial plans for continued development
12.06.2017 FN Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Finland, company expands on development plan
23.05.2017 FN Herantis Pharma granted a U.S. patent on therapeutic use of MANF
11.04.2017 FN Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders
23.03.2017 FN Herantis Pharmas clinical study with CDNF in Parkinsons disease authorized in Sweden
17.03.2017 FN Herantis Pharma's Annual Report 2016 published
06.03.2017 FN Herantis Pharma's clinical study with Lymfactin advances to high dose level
02.03.2017 FN Invitation to the Annual General Meeting of Herantis Pharma Plc
28.02.2017 ER Herantis Pharma Plc's Financial Statements Release January 1-December 31, 2016
23.01.2017 PR Herantis Pharma Plc publishes introductory video on its Lymfactin® with the leading lymphedema advocacy group LE&RN
10.01.2017 PR Herantis Pharma plc sponsors first CDNF MANF Symposium
02.01.2017 FN Herantis Pharma's Manager's Transactions
20.12.2016 FN Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2017
13.12.2016 FN Herantis Pharma Oyj - Manager's Transactions
12.12.2016 FN Herantis Pharma's Parkinson study wins EUR 6.0 million grant from the European Union Horizon 2020 program
25.10.2016 FN Herantis Pharma plc and Renishaw plc sign collaboration agreement on Parkinson's study
25.08.2016 ER Herantis Pharma Plc's Half year financial report January 1-June 30, 2016 (unaudited)
08.08.2016 FN EU funding application coordinated by Herantis Pharma has passed evaluation phase
11.07.2016 FN Herantis Pharma receives orphan designation in USA for CDNF for treatment of ALS
19.05.2016 FN Herantis Pharma Plc's Board decision on new stock option program for senior employees
18.05.2016 FN Herantis Pharma initiates patient recruitment for clinical study with Lymfactin® in breast cancer associated lymphedema
11.04.2016 FN Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders
29.03.2016 FN Herantis Pharma receives orphan designation of CDNF for treatment of ALS
17.03.2016 ER Herantis Pharma's Annual Report 2015 published
03.03.2016 FN Invitation to the Annual General Meeting of Herantis Pharma Plc
25.02.2016 FN Decision in arbitration proceedings between Herantis Pharma Plc's subsidiary Laurantis Pharma Ltd and Finvector Vision Therapies Ltd
25.02.2016 ER Herantis Pharma Plc Financial Statements Release January 1-December 31, 2015
14.01.2016 FN Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC
04.01.2016 FN Herantis Pharma elaborates on its outlook for 2016
10.12.2015 FN Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2016
13.11.2015 FN Finnish Medicines Agency authorization of first-in-man clinical study with Lymfactin
25.09.2015 FN Herantis Pharma plc shares subscribed with option rights
19.08.2015 ER Interim report January 1-June 30, 2015: Financially stable - new investments in regenerative medicine: CDNF and Lymfactin
01.07.2015 FN Herantis Pharma Certified Adviser change
30.06.2015 FN Herantis Pharma granted almost 3 million Euro government loan for Parkinson study
03.06.2015 PR Scientific publication suggests Herantis' CDNF improves long-term memory in mouse model of Alzheimers
03.06.2015 FN Herantis Pharma announces results from Phase 2 Cis-UCA Dry Eye study
01.06.2015 FN Herantis Pharma plc shares subscribed with option rights
10.04.2015 FN Constitutive meeting of the Board of Directors of Herantis Pharma Plc
09.04.2015 PR Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders
24.03.2015 ER Herantis Pharma's Annual Report 2014 published
18.03.2015 FN Herantis Pharma announces an internationally renowned Scientific Advisory Board with Professor Jonathan Knowles as Chairman
11.03.2015 FN Herantis Pharma's Phase 2 Dry Eye study recruitment completed ahead of schedule
09.03.2015 FN Finvector Vision Therapies has initiated arbitration proceedings against Herantis Pharma's subsidiary Laurantis Pharma and a number of its former shareholders
09.03.2015 FN Invitation to the Annual General Meeting of Herantis Pharma Plc
27.02.2015 ER Herantis Pharma Board of Directors' proposal for dividend
27.02.2015 ER Herantis Pharma financial statements report 2014
26.01.2015 FN Herantis Pharma Phase 1 study results of Cis-UCA Eye Drops published
07.01.2015 FN Herantis Pharma has initiated Phase 2 study with Cis-UCA Eye Drops in Patients with Dry Eye Syndrome, results expected in Q3/2015
18.12.2014 FN Herantis Pharma Plc's financial reporting in 2015
10.11.2014 FN Herantis Pharma plc shares subscribed with option rights
08.09.2014 FN Herantis Pharma announces FDA clearance of IND for Phase 2 study of Cis-UCA Eye Drops
15.08.2014 ER Interim report January 1-June 30, 2014: Pharmaceutical development programs advancing as planned - successful share issue enables progress according to strategy
04.06.2014 FN Final results of the initial public offering of Herantis Pharma
02.06.2014 FN Herantis Pharma successfully completes its initial public offering
12.05.2014 FN Herantis Pharma launches its initial public offering and applies for listing on First North
09.05.2014 PR Herantis Pharma considers listing to NASDAQ OMX First North Finland
29.04.2014 PR Herantis Pharma nominated new Board Directors

PR = PRESS RELEASE
ER = EARNINGS RELEASE
FN = FIRST NORTH